JP2014526562A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526562A5 JP2014526562A5 JP2014532075A JP2014532075A JP2014526562A5 JP 2014526562 A5 JP2014526562 A5 JP 2014526562A5 JP 2014532075 A JP2014532075 A JP 2014532075A JP 2014532075 A JP2014532075 A JP 2014532075A JP 2014526562 A5 JP2014526562 A5 JP 2014526562A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- disorder
- superoxide dismutase
- agent according
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 35
- 229940124597 therapeutic agent Drugs 0.000 claims 35
- 102000019197 Superoxide Dismutase Human genes 0.000 claims 29
- 108010012715 Superoxide dismutase Proteins 0.000 claims 29
- 239000003446 ligand Substances 0.000 claims 23
- 238000009472 formulation Methods 0.000 claims 17
- 230000003278 mimic effect Effects 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 238000002512 chemotherapy Methods 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 238000001959 radiotherapy Methods 0.000 claims 6
- 230000007935 neutral effect Effects 0.000 claims 5
- 239000000243 solution Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- 208000019693 Lung disease Diseases 0.000 claims 3
- 208000032376 Lung infection Diseases 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims 3
- 125000003963 dichloro group Chemical group Cl* 0.000 claims 3
- 208000010643 digestive system disease Diseases 0.000 claims 3
- 230000003176 fibrotic effect Effects 0.000 claims 3
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 208000030159 metabolic disease Diseases 0.000 claims 3
- 239000005022 packaging material Substances 0.000 claims 3
- 208000017520 skin disease Diseases 0.000 claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 239000007975 buffered saline Substances 0.000 claims 2
- 150000007942 carboxylates Chemical class 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000000451 tissue damage Effects 0.000 claims 2
- 231100000827 tissue damage Toxicity 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims 1
- 244000299906 Cucumis sativus var. sativus Species 0.000 claims 1
- 125000002579 carboxylato group Chemical group [O-]C(*)=O 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161539365P | 2011-09-26 | 2011-09-26 | |
| US61/539,365 | 2011-09-26 | ||
| PCT/US2012/056921 WO2013048965A1 (en) | 2011-09-26 | 2012-09-24 | Methods for treatment of diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017172825A Division JP6382416B2 (ja) | 2011-09-26 | 2017-09-08 | 疾患の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526562A JP2014526562A (ja) | 2014-10-06 |
| JP2014526562A5 true JP2014526562A5 (enExample) | 2015-11-12 |
| JP6267638B2 JP6267638B2 (ja) | 2018-01-24 |
Family
ID=47911939
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014532075A Active JP6267638B2 (ja) | 2011-09-26 | 2012-09-24 | 疾患の治療方法 |
| JP2017172825A Active JP6382416B2 (ja) | 2011-09-26 | 2017-09-08 | 疾患の治療方法 |
| JP2018145207A Active JP6736618B2 (ja) | 2011-09-26 | 2018-08-01 | 疾患の治療方法 |
| JP2020121417A Active JP7562125B2 (ja) | 2011-09-26 | 2020-07-15 | 疾患の治療方法 |
| JP2022200192A Active JP7697688B2 (ja) | 2011-09-26 | 2022-12-15 | 疾患の治療方法 |
| JP2025094341A Pending JP2025131753A (ja) | 2011-09-26 | 2025-06-05 | 疾患の治療方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017172825A Active JP6382416B2 (ja) | 2011-09-26 | 2017-09-08 | 疾患の治療方法 |
| JP2018145207A Active JP6736618B2 (ja) | 2011-09-26 | 2018-08-01 | 疾患の治療方法 |
| JP2020121417A Active JP7562125B2 (ja) | 2011-09-26 | 2020-07-15 | 疾患の治療方法 |
| JP2022200192A Active JP7697688B2 (ja) | 2011-09-26 | 2022-12-15 | 疾患の治療方法 |
| JP2025094341A Pending JP2025131753A (ja) | 2011-09-26 | 2025-06-05 | 疾患の治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US9149483B2 (enExample) |
| EP (1) | EP2760874A4 (enExample) |
| JP (6) | JP6267638B2 (enExample) |
| CN (2) | CN103906756B (enExample) |
| AU (5) | AU2012316397B2 (enExample) |
| CA (2) | CA3120505C (enExample) |
| HK (1) | HK1199261A1 (enExample) |
| WO (1) | WO2013048965A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2725023T3 (es) | 2006-10-12 | 2019-09-18 | Galera Labs Llc | Métodos para el tratamiento de la mucositis oral |
| EP2760874A4 (en) * | 2011-09-26 | 2015-04-08 | Galera Therapeutics Llc | METHOD FOR THE TREATMENT OF ILLNESSES |
| TWI746449B (zh) * | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
| RS60558B1 (sr) * | 2015-08-11 | 2020-08-31 | Galera Labs Llc | Pentaaza makrociklični prstenasti kompleksi koji poseduju oralnu bioraspoloživost |
| KR20180132939A (ko) * | 2016-05-03 | 2018-12-12 | 갈레라 랩스, 엘엘씨 | 암 치료를 위한 조합 요법 |
| JP7166634B2 (ja) * | 2016-09-01 | 2022-11-08 | ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー | ペンタアザ大環状環複合体およびアスコルビン酸化合物による組み合わせ癌療法 |
| CA3053779A1 (en) * | 2017-02-15 | 2018-08-23 | Galera Labs, Llc | Pentaaza macrocyclic ring complexes for local intestinal delivery |
| IL295620B2 (en) | 2017-04-13 | 2024-01-01 | Galera Labs Llc | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
| CA3090129A1 (en) * | 2018-01-31 | 2019-08-08 | Galera Labs, Llc | Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent |
| IL291989A (en) * | 2019-10-10 | 2022-06-01 | Galera Labs Llc | Production method for an aqueous formulation of a manganese-containing coordination complex, formulation and treatment method |
| US20230071463A1 (en) * | 2020-02-13 | 2023-03-09 | Teva Pharmaceuticals International Gmbh | Solid state forms of avasopasem manganese and process for preparation thereof |
| WO2025259817A1 (en) * | 2024-06-12 | 2025-12-18 | Galera Labs, Llc | Methods for reduced tissue damage from radiopharmaceuticals with superoxide-reducing agent |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4001212A (en) | 1973-10-03 | 1977-01-04 | E. I. Du Pont De Nemours And Company | Macrocyclic polyamines |
| US3930867A (en) | 1974-01-07 | 1976-01-06 | E. I. Du Pont De Nemours And Company | Macrocyclic polyamines as sensitizers for silver halide emulsions |
| JPS61226751A (ja) | 1985-03-30 | 1986-10-08 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀写真感光材料用処理液及びその処理方法 |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5096724A (en) | 1988-06-03 | 1992-03-17 | Aquanautics Corporation | Methods, compositions, and systems for ligand extraction |
| GB9001245D0 (en) | 1990-01-19 | 1990-03-21 | Salutar Inc | Compounds |
| EP0598753B1 (en) | 1991-07-19 | 1998-03-18 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
| CA2072934C (en) | 1991-07-19 | 2007-08-28 | Karl William Aston | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US6204259B1 (en) | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
| AU706642B2 (en) | 1994-04-22 | 1999-06-17 | G.D. Searle & Co. | Diagnostic image analysis with metal complexes |
| US6245758B1 (en) | 1994-05-13 | 2001-06-12 | Michael K. Stern | Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor |
| JPH0840941A (ja) | 1994-07-29 | 1996-02-13 | Kanegafuchi Chem Ind Co Ltd | 炎症性腸疾患治療製剤 |
| US6525041B1 (en) | 1995-06-06 | 2003-02-25 | Pharmacia Corporation | Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
| EP0844889A1 (en) | 1995-08-17 | 1998-06-03 | Monsanto Company | Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands |
| EP0846003A1 (en) | 1995-08-17 | 1998-06-10 | Monsanto Company | Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands |
| CZ39898A3 (cs) * | 1995-08-17 | 1998-07-15 | Monsanto Company | Biokonjugáty manganových komplexů makrocyklických ligandů obsahujících dusík účinné jako katalyzátory dismutace superoxidu |
| US20050171198A1 (en) | 1997-06-20 | 2005-08-04 | Metaphore Pharmaceuticals, Inc. | SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease |
| US20020128248A1 (en) | 1997-06-20 | 2002-09-12 | Metaphore Pharmaceuticals, Inc | SODm therapy for prevention and/or treatment of inflammatory disease |
| US6180620B1 (en) | 1997-06-20 | 2001-01-30 | G.D. Searle & Co. | Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals |
| US20060270639A1 (en) | 1997-06-20 | 2006-11-30 | Daniela Salvemini | Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs |
| US6214817B1 (en) * | 1997-06-20 | 2001-04-10 | Monsanto Company | Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| JP2991172B2 (ja) | 1997-10-24 | 1999-12-20 | 日本電気株式会社 | 半導体装置 |
| WO1999023097A1 (en) | 1997-11-03 | 1999-05-14 | Duke University | Substituted porphyrins |
| GB9817845D0 (en) | 1998-08-17 | 1998-10-14 | Glaxo Group Ltd | Chemical compounds |
| US6040330A (en) | 1999-01-08 | 2000-03-21 | Bionumerik Pharmaceuticals, Inc. | Pharmaceutical formulations of taxanes |
| AU5048400A (en) * | 1999-05-27 | 2000-12-18 | Monsanto Company | Biomaterials modified with superoxide dismutase mimics |
| US6448239B1 (en) | 1999-06-03 | 2002-09-10 | Trustees Of Princeton University | Peroxynitrite decomposition catalysts and methods of use thereof |
| JP2003502372A (ja) | 1999-06-23 | 2003-01-21 | エリック・エフ・バーンスタイン | 創傷治癒および光傷害の防止におけるニトロキシドの使用 |
| AU3679801A (en) | 2000-02-08 | 2001-08-20 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
| US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
| JP2004507487A (ja) | 2000-08-29 | 2004-03-11 | メファ・アクチェンゲゼルシャフト | 腸疾患治療薬 |
| US7166910B2 (en) | 2000-11-28 | 2007-01-23 | Knowles Electronics Llc | Miniature silicon condenser microphone |
| US6589948B1 (en) * | 2000-11-28 | 2003-07-08 | Eukarion, Inc. | Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases |
| US20020072512A1 (en) | 2000-12-08 | 2002-06-13 | Metaphore Pharmaceuticals, Inc | Method of preventing and treating HIV-mediated central nervous system damage |
| JP4331939B2 (ja) * | 2001-01-05 | 2009-09-16 | メタファー・ファーマシューティカルズ・インコーポレイテッド | サイトカイン活性を増強させ、そしてサイトカインの投与に伴う低血圧を治療するための組成物および方法 |
| DE60233317D1 (de) * | 2001-01-19 | 2009-09-24 | Nat Jewish Med & Res Center | Medikament zum schutz in der radiotherapie |
| EP1353655A2 (en) | 2001-01-26 | 2003-10-22 | Metaphore Pharmaceuticals Inc. | Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes |
| CA2439971A1 (en) * | 2001-03-02 | 2002-09-12 | Metaphore Pharmaceuticals, Inc. | Chromatography of metal complexes |
| US20040137638A1 (en) | 2002-03-04 | 2004-07-15 | Slomczynska Urszula J. | Chromatography of metal complexes |
| WO2002100395A1 (en) | 2001-06-08 | 2002-12-19 | Genzyme Corporation | Bismuth salts of anti-oxidants and radical scavengers for prevention and treatment of mucous membrane ulcers |
| US20040132706A1 (en) | 2001-10-05 | 2004-07-08 | Daniela Salvemini | Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension |
| IL161686A0 (en) | 2001-11-01 | 2004-09-27 | Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| WO2003051458A1 (en) * | 2001-12-14 | 2003-06-26 | Alcon, Inc. | Superoxide dismutase mimics for the treatment of ocular disorders and diseases |
| JP2005530738A (ja) | 2002-04-16 | 2005-10-13 | アイシス・イノヴェイション・リミテッド | 組織障害の予防及び／又は治療のためのクルクミン |
| US20050101581A1 (en) | 2002-08-28 | 2005-05-12 | Reading Christopher L. | Therapeutic treatment methods 2 |
| US6781231B2 (en) | 2002-09-10 | 2004-08-24 | Knowles Electronics Llc | Microelectromechanical system package with environmental and interference shield |
| US6798047B1 (en) | 2002-12-26 | 2004-09-28 | Amkor Technology, Inc. | Pre-molded leadframe |
| WO2005042718A2 (en) | 2003-10-31 | 2005-05-12 | Metaphore Pharmaceuticals, Inc. | Compositions and methods for treating, preventing, reversing and inhibiting pain |
| FR2863892B1 (fr) | 2003-12-18 | 2007-05-11 | Univ Paris Descartes | Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux |
| US7510710B2 (en) | 2004-01-08 | 2009-03-31 | The Regents Of The University Of Colorado | Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor |
| BRPI0509359A (pt) | 2004-03-29 | 2007-09-04 | Inotek Pharmaceuticals Corp | compostos de porfirina substituìda por piridila e métodos de empregos destes |
| US7262498B2 (en) | 2004-10-19 | 2007-08-28 | Hewlett-Packard Development Company, L.P. | Assembly with a ring and bonding pads formed of a same material on a substrate |
| US20070148154A1 (en) | 2004-12-17 | 2007-06-28 | Universite Rene Descartes (Paris V) | Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs |
| US8217166B2 (en) | 2005-05-05 | 2012-07-10 | Galera Therapeutics, Llc | Polyethylene glycolated superoxide dismutase mimetics |
| WO2006083508A2 (en) | 2005-01-10 | 2006-08-10 | Metaphore Pharmaceuticals Inc. | Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs |
| US20090099150A1 (en) | 2005-01-19 | 2009-04-16 | Daniela Salvemini | Methotrexate Combinations For Treating Inflammatory Diseases |
| WO2006105217A2 (en) | 2005-03-31 | 2006-10-05 | Schering Corporation | Spirocyclic thrombin receptor antagonists |
| CN2870352Y (zh) | 2005-12-23 | 2007-02-14 | 瑞声声学科技(深圳)有限公司 | 微机电系统传声器扣合式封装结构 |
| US20100158857A1 (en) | 2006-05-23 | 2010-06-24 | University Of Utah Research Foundation | Compositions and methods for the inhibition of endothelial nitric oxide synthase activity |
| US20080139525A1 (en) | 2006-08-31 | 2008-06-12 | The Brigham And Women's Hospital, Inc. | Antioxidant therapies |
| WO2008033466A2 (en) | 2006-09-14 | 2008-03-20 | Combinatorx (Singapore) Pre. Ltd. | Compositions and methods for treatment of viral diseases |
| ES2725023T3 (es) | 2006-10-12 | 2019-09-18 | Galera Labs Llc | Métodos para el tratamiento de la mucositis oral |
| TWI333264B (en) | 2007-01-10 | 2010-11-11 | Advanced Semiconductor Eng | Packaging structure and method of mems microphone |
| EP2190453A2 (en) * | 2007-09-11 | 2010-06-02 | Mondobiotech Laboratories AG | Use of trp6-triptorelin and d-leu6-leuprolide as therapeutic agents |
| WO2009111294A1 (en) | 2008-02-29 | 2009-09-11 | Eagle Pharmaceuticals, Inc. | Topotecan ready to use solutions |
| MX2010011307A (es) | 2008-04-15 | 2010-11-09 | Intermune Inc | Nuevos inhibidores de la replicacion del virus de hepatitis c. |
| EP2296645B1 (en) * | 2008-05-22 | 2014-11-19 | Galera Therapeutics, LLC | Combination antitumor therapy |
| CN106432474A (zh) | 2010-03-12 | 2017-02-22 | 艾伯维生物医疗股份有限公司 | Ctla4蛋白和其用途 |
| US20120207687A1 (en) | 2011-01-14 | 2012-08-16 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Topical formulations of targeted nitroxide agents |
| EP2760874A4 (en) | 2011-09-26 | 2015-04-08 | Galera Therapeutics Llc | METHOD FOR THE TREATMENT OF ILLNESSES |
| US9238659B2 (en) | 2012-11-19 | 2016-01-19 | The University Of Hong Kong | Method of using binuclear gold (I) compounds for cancer treatment |
| RS60558B1 (sr) | 2015-08-11 | 2020-08-31 | Galera Labs Llc | Pentaaza makrociklični prstenasti kompleksi koji poseduju oralnu bioraspoloživost |
| KR20180132939A (ko) | 2016-05-03 | 2018-12-12 | 갈레라 랩스, 엘엘씨 | 암 치료를 위한 조합 요법 |
| JP7166634B2 (ja) | 2016-09-01 | 2022-11-08 | ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー | ペンタアザ大環状環複合体およびアスコルビン酸化合物による組み合わせ癌療法 |
| US20190350867A1 (en) | 2016-12-27 | 2019-11-21 | Soon Kap Hahn | Prevention of local tumor recurrence following surgery using sustained and/or delayed release of medicaments contained in micro-particles |
| CA3053779A1 (en) | 2017-02-15 | 2018-08-23 | Galera Labs, Llc | Pentaaza macrocyclic ring complexes for local intestinal delivery |
| KR20190141690A (ko) | 2017-04-13 | 2019-12-24 | 갈레라 랩스, 엘엘씨 | 펜타아자 마크로시클릭 고리 복합체를 사용한 조합 암 면역요법 |
| EP3388082A1 (en) | 2017-04-13 | 2018-10-17 | Galera Labs, LLC | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
| IL295620B2 (en) | 2017-04-13 | 2024-01-01 | Galera Labs Llc | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
| CA3090129A1 (en) | 2018-01-31 | 2019-08-08 | Galera Labs, Llc | Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent |
-
2012
- 2012-09-24 EP EP20120835035 patent/EP2760874A4/en active Pending
- 2012-09-24 JP JP2014532075A patent/JP6267638B2/ja active Active
- 2012-09-24 CA CA3120505A patent/CA3120505C/en active Active
- 2012-09-24 WO PCT/US2012/056921 patent/WO2013048965A1/en not_active Ceased
- 2012-09-24 US US13/625,617 patent/US9149483B2/en active Active
- 2012-09-24 CA CA2849456A patent/CA2849456C/en active Active
- 2012-09-24 AU AU2012316397A patent/AU2012316397B2/en not_active Ceased
- 2012-09-24 CN CN201280053322.1A patent/CN103906756B/zh active Active
- 2012-09-24 CN CN202010082500.XA patent/CN111467351A/zh active Pending
- 2012-09-24 HK HK14112775.0A patent/HK1199261A1/xx unknown
-
2015
- 2015-08-27 US US14/837,831 patent/US10137133B2/en active Active
-
2016
- 2016-10-20 AU AU2016247160A patent/AU2016247160B2/en not_active Ceased
-
2017
- 2017-09-08 JP JP2017172825A patent/JP6382416B2/ja active Active
-
2018
- 2018-08-01 JP JP2018145207A patent/JP6736618B2/ja active Active
- 2018-10-31 US US16/176,958 patent/US10493081B2/en active Active
-
2019
- 2019-02-27 AU AU2019201392A patent/AU2019201392B2/en not_active Ceased
- 2019-11-12 US US16/680,844 patent/US11826373B2/en active Active
-
2020
- 2020-07-15 JP JP2020121417A patent/JP7562125B2/ja active Active
- 2020-10-05 AU AU2020244613A patent/AU2020244613C1/en not_active Ceased
-
2022
- 2022-12-15 JP JP2022200192A patent/JP7697688B2/ja active Active
-
2023
- 2023-03-31 AU AU2023201978A patent/AU2023201978A1/en not_active Abandoned
- 2023-10-18 US US18/381,524 patent/US20250017944A1/en not_active Abandoned
-
2025
- 2025-06-05 JP JP2025094341A patent/JP2025131753A/ja active Pending
- 2025-09-19 US US19/334,255 patent/US20260076977A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014526562A5 (enExample) | ||
| JP2025131753A5 (enExample) | ||
| JP2018184465A5 (enExample) | ||
| JP2018035162A5 (enExample) | ||
| US12059397B2 (en) | Calcium lactate compositions and methods of use | |
| CN106687110B (zh) | 一种纯化的治疗性纳米粒子及其制备方法 | |
| JP2020183416A5 (enExample) | ||
| RU2010114042A (ru) | Применение пептида в качестве терапевтического средства | |
| CN109970987B (zh) | Mof材料、纳米载药材料、药物组合物及其应用 | |
| WO2007134534A1 (fr) | Solution aqueuse de composition pharmaceutique de 20(r)-ginsenoside rg3 et procédé correspondant | |
| JP2014088444A5 (enExample) | ||
| JP2014521658A5 (enExample) | ||
| JP2015524444A5 (enExample) | ||
| RU2010113989A (ru) | Применение пептида в качестве терапевтического средства | |
| JP2019512495A5 (enExample) | ||
| RU2017115990A (ru) | Ингаляционная лекарственная форма рапамицина для лечения легочной гипертензии | |
| JP2013542263A5 (enExample) | ||
| JP6029808B2 (ja) | 併用療法における（＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の使用方法 | |
| CN103370066B (zh) | 用于治疗癌症的包含威罗菲尼和干扰素的组合疗法 | |
| CN109498627A (zh) | 一种治疗肿瘤的药物组合物及其应用 | |
| RU2358730C2 (ru) | Производное эпотилона для лечения гепатомы и других раковых заболеваний | |
| JP2012525358A5 (enExample) | ||
| US20150283237A1 (en) | Ctla-4 blockade with metronomic chemotherapy for the treatment of cancer | |
| TW202128151A (zh) | 癌症治療方法 | |
| JP2014502608A5 (enExample) |